0001209191-23-050841.txt : 20230929 0001209191-23-050841.hdr.sgml : 20230929 20230929141640 ACCESSION NUMBER: 0001209191-23-050841 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230927 FILED AS OF DATE: 20230929 DATE AS OF CHANGE: 20230929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Huizenga Theodore Alan CENTRAL INDEX KEY: 0001603347 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36276 FILM NUMBER: 231294607 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc. CENTRAL INDEX KEY: 0001515673 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272546083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-483-8800 MAIL ADDRESS: STREET 1: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-27 0 0001515673 Ultragenyx Pharmaceutical Inc. RARE 0001603347 Huizenga Theodore Alan C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 0 1 0 0 SVP, Chief Accounting Officer 0 Common Stock 23614 D Stock Option (Right to Buy) 67.37 2023-09-27 4 A 0 2351 0.00 A 2027-03-01 Common Stock 2351 2351 D Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions. On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On September 27, 2023, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 784 shares on that date. /s/ Karah Parschauer, attorney-in-fact 2023-09-29